Prioritizing Delivery of Cancer Treatment During a COVID-19 Lockdown: The Experience of a Clinical Oncology Service in India

Abstract

PURPOSE A COVID-19 lockdown in India posed significant challenges to the continuation of radiotherapy (RT) and systemic therapy services. Although several COVID-19 service guidelines have been promulgated, implementation data are yet unavailable. We performed a comprehensive audit of the implementation of services in a clinical oncology department. METHODS A departmental protocol of priority-based treatment guidance was developed, and a departmental staff rotation policy was implemented. Data were collected for the period of lockdown on outpatient visits, starting, and delivery of RT and systemic therapy. Adherence to protocol was audited, and factors affecting change from pre-COVID standards analyzed by multivariate logistic regression. RESULTS Outpatient consults dropped by 58%. Planned RT starts were implemented in 90%, 100%, 92%, 90%, and 75% of priority level 1-5 patients. Although 17% had a deferred start, the median time to start of adjuvant RT and overall treatment times were maintained. Concurrent chemotherapy was administered in 89% of those eligible. Systemic therapy was administered to 84.5% of planned patients. However, 33% and 57% of curative and palliative patients had modifications in cycle duration or deferrals. The patient’s inability to come was the most common reason for RT or ST deviation. Factors independently associated with a change from pre-COVID practice was priority-level allocation for RT and age and palliative intent for systemic therapy. CONCLUSION Despite significant access limitations, a planned priority-based system of delivery of treatment could be implemented.

Care in the time of COVID-19: impact on the diagnosis and treatment of breast cancer in a large, integrated health care system

“…Several groups have described guideline-driven changes to their institutional breast care workflows during the initial phases of the pandemic [ 4 – 8 ], but data are limited on the clinical impact of pandemic-driven changes [ 9 – 13 ]. Furthermore, these reports have revealed significant variability in guideline adherence between institutions and even between physicians within the same institution [ 14 ].…”

Covid-19 and radiotherapy: a systematic review after 2 years of pandemic

“…The Covid-19 pandemic affected the regular RT delivery to oncologic patients, owing to the delay or cancelation of procedures with the likely effect of observing the worsening of local disease control and reduced survival rates in the future [ 241 , 249 , 259 , 263 , 267 , 274 , 279 , 280 , 285 , 286 ].…”

Evaluating Quality Indicators of Glioblastoma Care: Audit Results From an Indian Tertiary Care Cancer Center

“…Interim radiologic progression in 7 (6%) patients prompted switch of therapy, and 11 patients discontinued treatment for various reasons, including inability to visit the hospital during the COVID19 pandemic although we had a planned priority-level–based approach that allowed treatment to be delivered to the patients most in need. 27 Of 25 patients who could not be started on adjuvant TMZ, four patients had deterioration of performance status with stable disease, two patients died of lower respiratory tract infection, and the remainder were switched to salvage chemotherapy because of progressive disease. In contrast to the CBTRUS radiation information completeness of 69.5%, we had information of all patients since all patients were offered some treatment.…”